Neslihan SINIM
(Acıbadem Hastanesi, Göz Hastalıkları Bölümü, Kayseri, Türkiye)
Sarper KARAKÜÇÜK
(Anadolu Sağlık Merkezi, Göz Hastalıkları Anabilim Dalı, Kocaeli, Türkiye)
Yıl: 2020Cilt: 29Sayı: 1ISSN: 1300-1256 / 2717-7149Sayfa Aralığı: 30 - 34İngilizce

64 0
Posterior Segment Effects of Prostaglandin Analogues
Purpose: Prostaglandin (PG) analogues are commonly used in the treatment of glaucoma. In this study, we aimed to investigate the posteriorsegment effects of the drug with long-term use of topical PG analogue monotherapy in patients with the diagnosis of primary open angle glaucoma(POAG).Materials and Methods: Patients diagnosed with POAG and treated for 1 to 3 years were included in the study. A total of 25 patients treatedwith latanoprost monotherapy formed the 1st group, 25 patients who received dorzolamide timolol combination monotherapy constitutedthe 2nd group, 25 patients with brimonidine monotherapy formed the 3rd group and 31 healthy volunteers made up the 4th group. Routineophthalmological examination, intraocular pressure (IOP) measurement and fundus examinations were performed thoroughly. Central macularand choroidal thicknesses were measured by optical coherence tomography (OCT).Results: There was no signifi cant difference in the mean macular thickness between the groups. The mean choroidal thickness was signifi cantlyhigher in patients using PG analogue than the other groups. None of the patients had intraocular infl ammation or cystoid macular edema (CME).Conclusion: The choroidal thickness was signifi cantly higher in the group receiving topical latanoprost monotherapy than the other groups.None of the patients had CME or infl ammation. PG analogue monotherapy can be used safely in POAG cases. PG analogue therapy should bekept in mind in clinical conditions where choroidal thickness is signifi cant.
DergiAraştırma MakalesiErişime Kapalı
  • 1. Shah R, and Wormald RP. Glaucoma. BMJ Clin. Evid. 2011; 06: 703-710.
  • 2. Fajgenbaum M and Ansari E. Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines. A Retrospective, Non- Interventional, Single-Center UK Study. Adv Ther. 2017; 34: 2033-2044.
  • 3. Mastropasqua R, Fasanella V, Agnifi li L, Fresina M, Di Staso S, Di Gregorio A, Marchini G. and Ciancaglini M. Advance in the pathogenesis and treatment of normaltension glaucoma. Prog Brain Res. 2015; 221: 213-232.
  • 4. Konstas A.G, Maltezos A.C, Gandi S, Hudgins AC and Stewart WC. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 1999; 128: 15–20.
  • 5. Parentin F. Granulomatous anterior uveitis associated with bimatoprost: a case report. Ocul Immunol Infl amm 2003; 11: 67–71.
  • 6. Packer ., Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003; 29: 2242–2243.
  • 7. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002; 133:401–403.
  • 8. Artunay O, Senel A, Sengul A, Rasier R, Bahcecioglu H. Central serous chorioretinopathy associated with topical latanoprost therapy. Ocul Immunol Infl amm 2011; 19(6):453–455.
  • 9. Ozdemir H, Karacorlu M, Karacorlu SA. Serous detachment of macula in cystoid macular edema associated with latanoprost. Eur J Ophthalmol. 2008; 18(6):1014.
  • 10. Krishnamurthy R, Senthil S, Garudadri CS. Late postoperative choroidal detachment following an uneventful cataract surgery in a patient on topical latanoprost. BMJ Case Rep. 2015.
  • 11. Sezer T, Altinisik M, Koytak IA, Ozdemir MH. Koroid ve Optik Koherens Tomografi . Turk J Ophthalmol 2016; 46: 30- 37.
  • 12. Lima MC, Paranhos A Jr, Salim S. Visually signifi cant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma 2000; 9: 317–21.
  • 13. Halpern DL, Pasquale LR. Cystoid macular edema in aphakia and pseudophakia after use of PG analogs. Semin Ophthalmol. 2002; 17: 181–6.
  • 14. Yeh PC, Ramanathan S. Latanoprost and clinically signifi cant cystoid macular edema after uneventful phacoemulsifi cation with intraocular lens implantation. J Cataract Refract Surg 2002; 28: 1814–8,
  • 15. Kruse P, Rieck P, Sherif Z, Liekfeld A. Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason? Klin Monatsbl Augenheilkd 2006; 223:534–7
  • 16. Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S, and Kashiwagi K. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J. Glaucoma. 2001; 10: 233–236.
  • 17. Yeom HY, Hong S, Kim SS, Kim CY, Seong GJ. Infl uence of topical bimatoprost on macular thickness and volume in glaucoma patients with phakic eyes. Can J Ophthalmol. 2008; 43(5):563-6.
  • 18. Chang, JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, and Lightman S. Use of ocular hypotensive PG analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br. J. Ophthalmol. 2008; 92: 916–921
  • 19. Selen F, Tekeli O, Yanik O. Assesment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs.J Ocular Pharmacol Ther.Apr. 2017; 33(3): 170-175
  • 20. Terasaki H, Kase S, Shirasawa M. TNF-a decreases VEGF secretion in highly polarized RPE cells but increases it in non-polarized RPE cells related to crosstalk between JNK and NF-kB pathways. PLoS One. 2003; 8:e69994
  • 21. Nakayama M, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, Hirakata A. Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi- Harada disease. Retina. 2012; 32(10):2061–2069
  • 22. Maru ko I, Iida T, Sugano Y, Oyamada H, Sekiryu T, Fujiwara T, Spaide RF. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina. 2011; 31(3):510–517
  • 23. Aoya gi R, Hayashi T, Masai A, Mitooka K, Gekka T, Kozaki K, Tsuneoka H. Subfoveal choroidal thickness in multiple evanescent white dot syndrome. Clin Exp Optom. 2012; 95:212–217
  • 24. Kola M, Kalkisim A, Karkucak M. Evaluation of choroidal thickness in ankylosing spondylitis using optical coherence tomography. Ocul Immunol Infl amm. 2014; 22(6):434-8
  • 25. Kim M, Kim H, Kwon HJ. Choroidal thickness in Behcet’s uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes. Invest Ophthalmol Vis Sci. 2013; 54: 6033–6039
  • 26. Cheggour M, Gambrelle J. Massive choroidal detachment secondary to topical use of bimatoprost: Report of two cases. J Fr Ophtalmol 2012; 35:176–80
  • 27. Nakakura S, Noguchi A, Tabuchi H, Kiuchi Y.Bimatoprostinduced late-onset choroidal detachment after trabeculectomy: A case report and review of the literature. Medicine (Baltimore). 2017; 96(5):e5927
  • 28. Krishnamurthy R, Senthil S, Garudadri CS. Late postoperative choroidal detachment following an unevethfulcataract surgeryin a patient on topical latanoprost. BMJ Case Rep.2015; July 14
  • 29. Coban DT, Erol MK, Yucel O. Hemorrhagic choroidal detachment after use of anti-glaucomatous eye drops: case report. Arq Bras Oftalmol.2013; 76(5):309-10
  • 30. Caliskan S, Ugurbas SC, Alpay A, Ugurbas SH. Changes in the choroidal thickness and axial length upon mannitol infusion in patients with asymmetric intraocular pressure. J Glaucoma 2016; 25: 891–895.
  • 31. Boltz A, Schmidl D, Weigert G, et al. Effect of latanoprost on choroidal blood fl ow regulation in healthy subjects. Invest Ophthalmol Vis Sci. 2011; 52: 4410-5.
  • 32. Akyol N, Kalkisim A, Turk A, Kola M, Imamoglu H.I. Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/ timolol maleate 0.5% fi xed combination Cutan Ocul Toxicol, 2017; 36(4): 397–403

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.